These findings suggest that the combined administration of targeted PUMA and FASN inhibitors is a promising therapeutic strategy, validating our mechanistic insights and offering a potential path forward in ccRCC treatment. This evidence concerns the gene FASN and nonpapillary renal cell carcinoma.